<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00719407</url>
  </required_header>
  <id_info>
    <org_study_id>H9299-32566-01</org_study_id>
    <secondary_id>Thrasher 02827-0</secondary_id>
    <nct_id>NCT00719407</nct_id>
  </id_info>
  <brief_title>Neonatal Erythropoietin in Asphyxiated Term Newborns</brief_title>
  <acronym>NEAT</acronym>
  <official_title>Neonatal Erythropoietin in Asphyxiated Term Newborns: a Phase I Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Thrasher Research Fund</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>UCSF Benioff Children's Hospital Oakland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Santa Clara Valley Health &amp; Hospital System</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and pharmacokinetics of moderate to high&#xD;
      doses of erythropoietin in newborn infants with birth asphyxia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Newborn infants with birth asphyxia are at high risk of death or long-term neurologic&#xD;
      disability; yet therapies for birth asphyxia are currently limited. Erythropoietin (Epo) is a&#xD;
      FDA-approved drug that is an effective neuroprotective agent in animal models of birth&#xD;
      asphyxia. This is a phase I dose finding multi-center trial that will test the safety and&#xD;
      pharmacokinetics of Epo in human infants with birth asphyxia. The long-term objectives of the&#xD;
      proposed research are to reduce mortality and to decrease the risk of long-term disabilities&#xD;
      in infants who survive beyond the newborn period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serious adverse event</measure>
    <time_frame>14 days of life</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters</measure>
    <time_frame>1 to 11 days of life</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Hypoxic-ischemic Encephalopathy</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All enrolled patients will be in this single arm, who will receive experimental drug treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>erythropoietin</intervention_name>
    <description>250 U/kg/dose x 6 doses (n=3); 500 U/kg/dose x 6 doses (n=6); 1,000 U/kg/dose x 6 doses (n=7) 2,500 U/kg/dose x 6 doses (n=8)</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Procrit</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. â‰¥ 36 weeks gestational age&#xD;
&#xD;
          2. Perinatal depression (low Apgar score, need for resuscitation)&#xD;
&#xD;
          3. Moderate to severe encephalopathy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Specific aEEG findings&#xD;
&#xD;
          2. Intrauterine growth restriction&#xD;
&#xD;
          3. Severe congenital anomaly, genetic syndrome, metabolic disorder, arthrogryposis, TORCH&#xD;
             infection&#xD;
&#xD;
          4. Microcephaly&#xD;
&#xD;
          5. Infant older than 23.5 hours of age at the time of consent&#xD;
&#xD;
          6. Infant judged by an attending physician to be likely to die due to the severity of&#xD;
             illness&#xD;
&#xD;
          7. Polycythemia&#xD;
&#xD;
          8. Hypertension&#xD;
&#xD;
          9. No in-dwelling line&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>24 Hours</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yvonne W Wu, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <study_first_submitted>July 17, 2008</study_first_submitted>
  <study_first_submitted_qc>July 17, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 21, 2008</study_first_posted>
  <last_update_submitted>November 7, 2012</last_update_submitted>
  <last_update_submitted_qc>November 7, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 9, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Francisco</investigator_affiliation>
    <investigator_full_name>Yvonne Wu</investigator_full_name>
    <investigator_title>Professor of Neurology and Pediatrics</investigator_title>
  </responsible_party>
  <keyword>birth asphyxia</keyword>
  <keyword>neonatal encephalopathy</keyword>
  <keyword>hypoxic-ischemic encephalopathy</keyword>
  <keyword>neuroprotection</keyword>
  <keyword>neonate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Diseases</mesh_term>
    <mesh_term>Brain Ischemia</mesh_term>
    <mesh_term>Hypoxia-Ischemia, Brain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epoetin Alfa</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

